Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After A Year Of Prevnar Shortages, Wyeth Enters 2005 With Inventory On-Hand

This article was originally published in The Pink Sheet Daily

Executive Summary

Wyeth enters 2005 with "significant" Prevnar inventory, the company said during a quarterly earnings call Jan. 31

You may also be interested in...



Adult Pneumococcal Vaccinations Could Increase Under CDC Program

The Centers for Disease Control & Prevention is awarding a two-year contract to evaluate whether a proactive pharmacist pneumococcal vaccination program would increase adult use of the vaccine. Merck’s Pneumovax 23 is the only pneumococcal vaccine commercially available for adults.

Adult Pneumococcal Vaccinations Could Increase Under CDC Program

The Centers for Disease Control & Prevention is awarding a two-year contract to evaluate whether a proactive pharmacist pneumococcal vaccination program would increase adult use of the vaccine. Merck’s Pneumovax 23 is the only pneumococcal vaccine commercially available for adults.

Prevnar, Effexor, Enbrel Powering Strong First Quarter For Wyeth

Normalization of Prevnar demand after the correction of supply problems will play a major role in delivering first quarter earnings per share levels significantly higher than analyst estimates, CFO Martin says. Third quarter results may be down compared to 2004 because of high anticipated R&D spending.

Topics

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel